Analyst Price Target is $47.50
▲ +74.63% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Q32 Bio in the last 3 months. The average price target is $47.50, with a high forecast of $50.00 and a low forecast of $45.00. The average price target represents a 74.63% upside from the last price of $27.20.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Q32 Bio. This Buy consensus rating has held steady for over two years.
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.
Read More